Ladenburg Thalmann Financial Services Inc. Acquires 327 Shares of Hill-Rom Holdings, Inc. (NYSE:HRC)

Ladenburg Thalmann Financial Services Inc. boosted its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 14.9% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,526 shares of the medical technology company’s stock after acquiring an additional 327 shares during the quarter. Ladenburg Thalmann Financial Services Inc.’s holdings in Hill-Rom were worth $264,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in HRC. First Trust Advisors LP boosted its holdings in Hill-Rom by 156.7% during the 1st quarter. First Trust Advisors LP now owns 346,685 shares of the medical technology company’s stock valued at $36,700,000 after acquiring an additional 211,643 shares during the period. Rehmann Capital Advisory Group boosted its holdings in Hill-Rom by 82.1% during the 1st quarter. Rehmann Capital Advisory Group now owns 539 shares of the medical technology company’s stock valued at $57,000 after acquiring an additional 243 shares during the period. Advisory Services Network LLC boosted its holdings in Hill-Rom by 31.3% during the 1st quarter. Advisory Services Network LLC now owns 1,050 shares of the medical technology company’s stock valued at $111,000 after acquiring an additional 250 shares during the period. Nordea Investment Management AB boosted its holdings in Hill-Rom by 0.9% during the 1st quarter. Nordea Investment Management AB now owns 51,359 shares of the medical technology company’s stock valued at $5,437,000 after acquiring an additional 439 shares during the period. Finally, FMR LLC boosted its holdings in Hill-Rom by 17.8% during the 1st quarter. FMR LLC now owns 1,870,034 shares of the medical technology company’s stock valued at $197,962,000 after acquiring an additional 282,069 shares during the period. Institutional investors and hedge funds own 82.61% of the company’s stock.

In related news, SVP Paul Sherwood Johnson sold 6,470 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $104.26, for a total transaction of $674,562.20. Following the completion of the transaction, the senior vice president now owns 8,215 shares of the company’s stock, valued at approximately $856,495.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.73% of the stock is currently owned by corporate insiders.

Shares of NYSE:HRC traded up $0.68 during trading on Friday, hitting $103.97. The stock had a trading volume of 285,695 shares, compared to its average volume of 451,472. Hill-Rom Holdings, Inc. has a 12 month low of $81.85 and a 12 month high of $111.63. The company has a market capitalization of $6.90 billion, a PE ratio of 20.47, a PEG ratio of 1.88 and a beta of 0.83. The firm’s fifty day moving average is $102.71 and its 200 day moving average is $103.06. The company has a quick ratio of 1.10, a current ratio of 1.31 and a debt-to-equity ratio of 1.13.

Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, November 1st. The medical technology company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.65 by $0.04. Hill-Rom had a return on equity of 21.67% and a net margin of 5.24%. The firm had revenue of $782.80 million during the quarter, compared to analyst estimates of $759.14 million. During the same quarter in the prior year, the company earned $1.63 EPS. The business’s revenue was up 3.1% compared to the same quarter last year. Equities research analysts expect that Hill-Rom Holdings, Inc. will post 5.52 EPS for the current fiscal year.

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $125.00 price target on shares of Hill-Rom in a research report on Tuesday, August 6th. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. UBS Group upped their price target on Hill-Rom from $122.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Barclays upped their price target on Hill-Rom from $108.00 to $116.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 6th. Finally, KeyCorp upped their price target on Hill-Rom from $114.00 to $125.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Hill-Rom presently has an average rating of “Buy” and an average price target of $118.67.

Hill-Rom Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Recommended Story: Municipal Bonds

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News